Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30

Class I - Dangerous

What Should You Do?

  1. Check if you have this product:
    Lot YJ0152, Expiry: 01/31/2028.
  2. Do not eat it: Even if it looks and smells fine, do not consume this product.
  3. Throw it away or return it: You can return the product to the store for a full refund.
  4. Seek medical attention if needed: If you've consumed this product and feel unwell, contact your doctor immediately.
  5. Report problems: Report any issues to the FDA's Safety Reporting Portal.

⚠️ Emergency: If you experience severe symptoms after consuming this product, call 911 or Poison Control at 1-800-222-1222.

Recall Details

Company:
ASTRAZENECA PHARMACEUTICALS
Reason for Recall:
Lack of Assurance of Sterility:
Classification:
Class I - Dangerous

Dangerous or defective products that predictably could cause serious health problems or death.

Status:
ongoing

Product Information

Full Description:

Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30

Product Codes/Lot Numbers:

Lot YJ0152, Expiry: 01/31/2028.

Official Source

Always verify recall information with the official FDA source:

View on FDA.gov

FDA Recall Number: D-0028-2026

Related Recalls

Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

May 25, 2017 Prescription Drugs Nationwide View Details →

Defective Delivery System: Some units have actuation counters set to a number other than 60.

Feb 5, 2016 Prescription Drugs Nationwide View Details →